Moderna and the University of Oxford said the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) authorized a Phase I/II study of mRNA-4194, Moderna’s mRNA-based cancer vaccine for Lynch syndrome. The authorization allows the investigational vaccine to move into clinical evaluation in the UK. mRNA-4194 is designed for immune priming in individuals with Lynch syndrome, a hereditary condition that increases risk of multiple cancers. The study authorization in the UK follows Moderna’s broader push into mRNA cancer vaccine platforms. For biotech developers, regulator clearance is an important step toward establishing feasibility, immunogenicity, and early safety signals in defined high-risk populations. The move also highlights how MHRA continues to greenlight mRNA oncology programs while they refine trial designs for inherited cancer risk settings.